Drug intelligence / Profile preview

fluoroethoxybenzovesamicol

Development stage: Phase 2
Lead developer: McGill University
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Fluoroethoxybenzovesamicol (FEOBV), specifically the [18F]-labeled enantiomer, is a radiopharmaceutical small molecule that acts as a highly selective ligand for the vesicular acetylcholine transporter (VAChT). It is used as a positron emission tomography (PET) imaging tracer to provide a direct in vivo measurement of presynaptic cholinergic terminal density and integrity in the central nervous system. Unlike previous cholinergic biomarkers that measure both pre- and post-synaptic expressions, FEOBV specifically targets VAChT, making it a valuable tool for studying cholinergic denervation in neurodegenerative conditions such as Parkinson's disease, Alzheimer's disease, Down syndrome, and progressive supranuclear palsy. It is also utilized in research to evaluate the effects of cognitive training on cholinergic network health in aging populations.

Other names: [18F]fluoroethoxybenzovesamicol18F-FEOBVfluoroethoxy-benzovesamicol

Targets

SLC18A3 (Vesicular acetylcholine transporter)

Beyond the preview

Go deeper on fluoroethoxybenzovesamicol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluoroethoxybenzovesamicol.

Explore the full profile